© Copyright 2015 Galapagos NV

Filgotinib blocks JAK/STAT signaling in

mouse colitis

THE FIRST JAK1-SELECTIVE INHIBITOR, FILGOTINIB, DISPLAYS SIMILAR MOLECULAR ACTIVITY IN THE GUT OF MICE WITH DSS-INDUCED COLITIS AND IN CULTURES OF COLON BIOPSIES FROM INFLAMMATORY BOWEL DISEASE PATIENTSCarole Delachaume1, Veerle De Vriendt2, Debby Laukens3, Béatrice Vayssière1, Didier Merciris1,Steve De Vos2,Marie-Christine Ceccotti1, Christelle David1, Laetitia Perret1, Martine De Vos3, Reginald Brys2 and René Galien1 1Galapagos SASU, Romainville, France; 2Galapagos NV, Mechelen, Belgium; 3Ghent University Hospital, Ghent, Belgium

IntroductionFilgotinib (known as GLPG0634) is a JAK inhibitor selective for JAK1 over the 3 other family members (JAK2, JAK3 and TYK2) in biochemical and human whole blood assays. It is efficacious in arthritis and colitis mouse models. Filgotinib is currently being assessed as a treatment for Crohn’s disease (CD) in a Phase 2 study. The objective of this study was to compare signalling mechanisms, in particular JAK1 inhibition-related effects, regulated by filgotinib in mouse IBD model and in ex vivo human colon biopsies.

Figure 1. Pharmacokinetic results after s.c. dosing (left) and after oral dosing (right)

ConclusionsThese data highlight the importance of JAK1/STAT3 pathway observed in both pre-clinical mouse colitis model & human colon biopsy culture, further pointing out the role of JAK1 in the etiology of IBD. These data suggest that filgotinib, a JAK1-selective inhibitor, may be beneficial in treating CD patients and support its evaluation in a clinical study.

Poster available online at: www.glpg.com

Disclosures: AbbVie has provided funding to Galapagos for the development of GLPG0634

C. Delachaume, V. De Vriendt, B. Vayssière, D. Merciris, S. De Vos, M.C. Ceccotti, C. David, L. Perret, R. Brys and R. Galien are employees of GalapagosThis work was supported by a grant from IWT, N°120550

MethodsChronic mouse colitis model· Chronic colitis induction in Balb/c mice: 4% dextran sodium sulphate

(DSS) in drinking water for 5/7 days in 3 successive periods.· Treatments: 30 mg/kg Filgotinib QD orally for 16 days· Disease Activity Index score (DAI): composite score based on daily

assessment of weight loss, rectal bleeding and stool consistency.· Histology: scoring of severity and extent of inflammation and

epithelial damage, cell infiltration by immunohistochemistry (IHC) · JAK/STAT target engagement in colon tissue was evaluated by

measuring STAT3 phosphorylation using IHC and gene expression by qPCR

IBD patient colon biopsy culture· Inflamed colon biopsies from 8 IBD patients were treated with

filgotinib 5µM and JAK/STAT target engagement was evaluated by measuring STAT3 phosphorylation after 24h using immunoassay and gene expression after 18h by qPCR

Fig. 1. Efficacy of filgotinib on disease activity index and colon stretching

Filgotinib prevents mouse colitis

control DSS/vehicle DSS/30 mg/kg filgotinib

Fig. 2. Efficacy of filgotinib on colon lesion histological score

Fig. 3. Efficacy of filgotinib on inflammation-driven immune cell infiltration

Filgotinib blocks JAK/STAT signaling in IBD patient

colon biopsies

Fig. 4. Efficacy of filgotinib on STAT3 phosphorylation

Control

DSS/vehicle

DSS/filgotinib

Fig. 5. Efficacy of filgotinib on JAK1-dependent and inflammation genes

Fig. 6. Efficacy of 5µM filgotinib on STAT3 phosphorylation

Fig. 7. Efficacy of filgotinib 5µM on JAK1-dependent and inflammation genes

0

1

2

3

4

5

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

dise

ase

activ

ity in

dex

time (days)

0

2

4

6

colo

n le

sion

sco

re

0.000

0.005

0.010

0.015

0.020

pSTA

T3

stai

ning

in

dex

0

5

10

15

20

25

cell

dens

ity (

cells

/mm

2)

0

2

4

6

8

cell

surf

ace

(%)

0

1

2

3

4

T c

ell s

urfa

ce (

%)

***

** ***

***

***

***

Neutrophil Macrophage T cell

vehicle

filgotinib

**

IL6MX1 SOCS3 TNFa

JAK1-dependent inflammation

**** * *IL6Mx1 SOCS3 TNFa

** *** *** *** ** ** ***

JAK1-dependent inflammation

15

19

23

27

colo

n/in

test

ine

leng

th (

%)

control DSS/vehicle DSS/filgotinib

0.1mm 0.1mm 0.1mm

control

DSS/vehicle

DSS/filgotinib

P1586